TREATMENT OPTIMIZATION BY HIGH DOSE IMATINIB: RANDOMIZED COMPARISON OF IMATINIB 800 MG VS. IMATINIB 400 MG VS. IMATINIB 400 MG + IFN IN NEWLY DIAGNOSED BCR-ABL POSITIVE CHRONIC PHASE (CP) CML WITH REGARD TO MMR AT MONTH 12. THE GERMAN CML-STUDY IVR. Hehlmann,S. Jung-Munkwitz,M. Lauseker,A. Leitner,N. Pletsch,U. Proetel,M. Mueller,C. Haferlach,B. Schlegelberger,S. Schnittger,C. Waller,A. Neubauer,L. Kanz,M. Haenel,J. Mayer,F. Stegelmann,R. Fuchs,S. Koschmieder,L. Balleisen,M. Pfirrmann,G. Ehninger,T. Fischer,D. Hossfeld,H. J. Kolb,S. Krause,C. Nerl,H. Pralle,A. Gratwohl,A. Tobler,H. Heimpel,J. Hasford,A. Hochhaus,S. Saussele,B. HanfsteinHAEMATOLOGICA-THE HEMATOLOGY JOURNAL（2010）引用 0|浏览14AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
